Adaptimmune Therapeutics PLC

NASDAQ:ADAPUnited States

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and have reported clinical responses (per RECIST 1.1) in seven solid tumor indications. Its platform enables to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cells, which use genetically engineered T-cell receptors; Tumor Infiltrating Lymphocytes (TiLs) where a patient’s own T-cells are co-administered with its next generation technology, and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its clinical trials include Spearhead-1 Phase II trial with afamitres gene autoleucel; Surpass Phase I Trial with ADP-A2M4CD8, and others.

Contact Information

Headquarters

60 Jubilee AvenueABINGDON, United Kingdom OX14 4RX

Phone

123-543-0000

Fax

---

Executives

Non-Executive Independent Chairman of the Board

David Mott

Chief Executive Officer, Director

Adrian Rawcliffe

Chief Financial Officer

Gavin Wood

Chief Operating Officer

William Bertrand

Chief Scientific Officer

Joanna Brewer